GLP-1 drugs are driving demand for dairy proteins, particularly whey. Companies such as Danone, Yili, Arla and Saputo have pointed to GLP-1s as a demand driver. Yet products explicitly declaring suitability for GLP-1 users are rare. GLP-1s did not create this demand, but merely exacerbated it.